02576nam 2200445 450 991067705210332120191111074841.01-118-67583-51-118-67577-01-118-67574-6(CKB)4330000000006745(MiAaPQ)EBC5940462(PPN)243211341(EXLCZ)99433000000000674520191111d2020 uy 0engurcnu||||||||txtrdacontentcrdamediacrrdacarrierIn vitro drug release testing of special dosage forms /edited by Nikoletta Fotaki, Sandra KleinHoboken, New Jersey ;Chichester, West Sussex, England :Wiley,[2020]©20201 online resource (315 pages)Advances in pharmaceutical technology1-118-34147-3 "In the mid 1960s people realized that drug dissolution/release has a significant impact on the therapeutic effect of orally administered drugs. Both the United States Food and Drug Administration (FDA) and United States Pharmacopoeia introduced dissolution requirements for oral drug products and the first dissolution tests became a quality control (QC) tool to ensure batch-to-batch consistency. As a consequence, from the 1970s on, several dissolution test methods were adopted as official QC methods for solid oral dosage forms. In the late 1990s, the increasing number of official dissolution apparatus and dissolution methods in the USP was complemented by the release of various FDA guidances pertaining to in vitro dissolution testing of solid oral dosage forms and its application from a regulatory point of view. Since then dissolution/drug release testing has expanded considerably with a variety of apparatus and methods in international pharmacopoeia and numerous international guidances and nowadays not only addresses questions of quality control but also plays an important role in screening of formulations and is also an important tool in proving bioequivalence of different drug products"--Provided by publisher.Advances in pharmaceutical technology.Solid dosage formsSolid dosage forms.615.19 Fotaki Nikoletta1973-Klein Sandra1970-MiAaPQMiAaPQMiAaPQBOOK9910677052103321In vitro drug release testing of special dosage forms3068772UNINA